Trials / Withdrawn
WithdrawnNCT04870801
An Alternative Way To Deliver Oxygen To People
Evaluation of Respirogen Oxygen Microbubble Technology: Efficacy for Human Use During Rest in Normal and Low-oxygen Environments
- Status
- Withdrawn
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Christopher Bell · Academic / Other
- Sex
- All
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
The availability of oxygen is a crucial prognostic indicator for outcomes pertinent to many chronic diseases. Accordingly, interventions that might increase oxygen availability have obvious beneficial clinical application. In this regard, Respirogen Micro-Oxygen (RMO) technology holds considerable promise. Data from experimental animal models of lung injury suggest administration of RMO is a feasible method to deliver oxygen in a manner independent of pulmonary function. Our ultimate long-term goal is to provide a product that can be used to deliver oxygen to humans experiencing respiratory distress and pulmonary dysfunction In this first exploratory study, our goal is to begin to understand the physiological responses to enteral (rectal) delivery of RMO in low-oxygen environments in healthy adults at rest.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Respirogen Micro-Oxygen | Enteral (rectal) delivery of Respirogen Micro-Oxygen |
Timeline
- Start date
- 2022-01-01
- Primary completion
- 2024-01-01
- Completion
- 2024-01-01
- First posted
- 2021-05-04
- Last updated
- 2022-06-30
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04870801. Inclusion in this directory is not an endorsement.